China's Ascletis raises $35M; Sancilio swings for $86M IPO;

@FierceBiotech: ICYMI yesterday: Gene therapy upstart Audentes bags a new program in buyout. Article | Follow @FierceBiotech

@JohnCFierce: From the early hours file: AstraZeneca backs $80M round for ADC's antibody warhead tech. News | Follow @JohnCFierce

@DamianFierce: ICYMI yesterday: AstraZeneca auctions off troubled psoriasis drug to Valeant in $445M deal. More | Follow @DamianFierce

> Chinese biotech Ascletis raised $35 million in equity financing, cash it plans to put toward its efforts to develop hepatitis C treatments for the Asian market. News

> Baxalta ($BXLT) is pairing up with Switzerland's Novimmune to develop bispecific antibodies for an undisclosed disease target. Release

> Florida's Sancilio Pharmaceuticals filed for an $86 million IPO, looking to raise cash for its lipid-based candidates in sickle cell disease, short bowel syndrome, high triglycerides and non-alcoholic fatty liver disease (NAFLD). More

> Gilead Sciences' ($GILD) two-drug HIV combo F/TAF met its primary goal of measuring up to Truvada in a Phase III trial. Item

Medical Device News

@FierceMedDev: Agena Bioscience opening office in China, aims to sell spectrometry systems in the country. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Quanterix and Banyan Biomarkers forge ahead with brain injury diagnostic tech. More | Follow @VarunSaxena2

@EmilyWFierce: DynoSense selects Chinese marketing partner for handheld monitoring device. Story | Follow @EmilyWFierce

> HeartWare looks to diversify into mitral valve repair with $929M purchase of Valtech Cardio. Story

> FDA partners with nonprofit device incubator Fogarty Institute to improve approval efficiency. More

Pharma News

@FiercePharma: India's Maharashtra state asks blood banks to send plasma to Reliance Life Sciences in albumin shortage. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Jardiance and its CV data? They're no knockout punch for stalwart Januvia, Merck says. Report | Follow @CarlyHFierce

> Valeant doubles size of its HQ as deal spree continues. More

> European pharma lobby says 'non' to French funding for off-label Avastin. Article

Biotech Research News

> TGen IDs targets for nonalcoholic fatty liver disease. Item

> Ziopharm tests new approach to engineering CAR-Ts for solid tumors. Report

> Eta-amyloid discovered in Alzheimer's adds new piece to the complex puzzle. More

> New research highlights role of SKA2 gene in PTSD, suicide. Article

> Gene variant linked to a 10-year delay in Alzheimer's onset. Story

Diagnostics News

> FDA scolds Cepheid for manufacturing issues in Sweden. More

> Exact Sciences wins CMS panel vote for Cologuard pricing. Report

> JAMA: Two genetic tests, not one, could work better at diagnosing autism. More

> Agena Bioscience opening office in China, aims to sell spectrometry systems in the country. Story

> FDA scolds Cepheid for manufacturing issues in Sweden. Article

Pharma Marketing News

> Bristol-Myers' Opdivo snags FDA priority review for bigger lung cancer use. Item

> Pharma TV ads are good for the business bottom line, study says. Report

> New Pradaxa antidote study preps Boehringer for market-share turnaround: ESC. Story

> AstraZeneca sales team revving up for new Brilinta marketing push. More

> Valeant bets the odds on AZ's psoriasis med in $100M-plus development deal. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.